Life sciences

Global Genome Editing Market Segment Forecasts 2021-2028: Cell Line Engineering Dominates the Market - ResearchAndMarkets.com

Retrieved on: 
월요일, 9월 6, 2021
Biotechnology, Genetics, Health, Branches of biology, Biology, Life sciences, Genetic engineering, Biotechnology, Emerging technologies, Molecular biology, Biological engineering, Genome editing, Zinc finger nuclease, CRISPR, Transcription activator-like effector nuclease

The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR, ZFN, TALEN), by Delivery Method, by Application, by Mode, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR, ZFN, TALEN), by Delivery Method, by Application, by Mode, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global genome editing market size is expected to reach USD 19.4 billion by 2028.
  • The market is expected to expand at a CAGR of 22.9% from 2021 to 2028.
  • Moreover, the Cas protein system is gaining traction in the development of point-of-care diagnostics, thereby driving investment flow in diagnostic applications
    China is reported to be the first country to have successfully transferred genetically edited cells into humans, to boost immunity and treat lung cancer, thereby driving the market
    Chapter 1 Genome Editing Market: Research Methodology
    Chapter 2 Genome Editing Market: Executive Summary
    Chapter 3 Genome Editing Market: Industry Outlook
    Chapter 4 Genome Editing Market: Technology Business Analysis
    Chapter 5 Genome Editing Market: Delivery Method Business Analysis
    Chapter 6 Genome Editing Market: Application Business Analysis
    Chapter 7 Genome Editing Market: End-Use Business Analysis
    Chapter 8 Genome Editing Market: Mode Business Analysis
    Chapter 9 Genome Editing Market: Regional Business Analysis
    Chapter 10 Genome Editing Market: Competitive Landscape

Worldwide Companion Diagnostics Market to 2026 to be Driven by Significant Partnerships and Collaborations for Development

Retrieved on: 
월요일, 9월 6, 2021
Companies, Life sciences, Industry economics), Medical tests, Medical software, Qiagen, Molecular diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies

The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.

Key Points: 
  • The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.
  • In addition, improvements in regulatory guidelines and the growing need for targeted therapies are also driving the global companion diagnostics market.
  • Increasing incidences of cancer has driven the adoption of companion diagnostics for developing drugs in cancer treatment.
  • Oncology is the leading segment in terms of revenue in global companion diagnostics market with around 82.72% market share.

GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug

Retrieved on: 
월요일, 9월 6, 2021
Life sciences, Medical specialties, Biology, Immunology, Biotechnology, Pharmaceutical industry, Immune system, Antibody, Glycoproteins, Monoclonal antibody, CD135, Biopharmaceutical

NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.

Key Points: 
  • NANJING, China, Sept. 6, 2021 /PRNewswire/ --GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production.
  • "GenScript ProBio and SYNIMMUNE GmbH entered into collaboration on FLYSYN antibody project for technology transfer and manufacturing of drug substance and drug product for Clinical Phase II trials, it is our pleasure to support this innovative antibody project," said Dr. Brian Min, CEO of GenScript ProBio, "GenScript ProBio's GMP manufacturing center meets global regulatory requirements.
  • We are confident that GenScript ProBio will produce SYNIMMUNE's lead antibody drug product FLYSYN to all global quality GMP standards within the agreed upon timeline.
  • GenScript ProBio's innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization.

Teknova to Report Second Quarter 2021 Financial Results on August 11

Retrieved on: 
수요일, 8월 4, 2021
Biotechnology, Life sciences, Biology, Articles, Biopharmaceuticals, Bioproduction, Bioprocess, Molecular diagnostics, Reagent

HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.

Key Points: 
  • HOLLISTER, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products including drug therapies, novel vaccines, and molecular diagnostics, today announced that it will report its financial results for the second quarter of 2021 on Wednesday, August 11, 2021, following the close of market.
  • ET to discuss the Companys financial results and provide a business update.
  • Participants may access the live webcast on the Investor Relations section of the Teknova website, where it will be archived for 30 days, and at this link: https://edge.media-server.com/mmc/p/avgvftny .
  • Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics.

Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress

Retrieved on: 
수요일, 8월 4, 2021
Health sciences, Pharmaceutical sciences, Revenue, Pharmaceutical industry, Life sciences

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today reported business highlights and financial results for the second quarter ended June 30, 2021.

Key Points: 
  • Total Revenue: Revenue was $13.4 million for the second quarter of 2021, which was derived from the Companys collaborations with Janssen and Ono Pharmaceutical.
  • R&D Expenses: Research and development expenses were $48.0 million for the second quarter of 2021, which includes $8.6 million of non-cash stock-based compensation expense.
  • ET to review financial and operating results for the quarter ended June 30, 2021.
  • As a result, investors, the media, and others interested in Fate Therapeutics are encouraged to review this information on a regular basis.

Sage Therapeutics to Present at Upcoming August Investor Conferences

Retrieved on: 
수요일, 8월 4, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Life sciences, Biotechnology, Articles, Pharmaceutical industry, Genuity, Biopharmaceutical

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:

Key Points: 
  • Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conferences in August:
    2021 Wedbush PacGrow Healthcare Virtual Conference: Barry Greene, Chief Executive Officer of Sage Therapeutics, will be a featured speaker on the panel, The Brains of the Operation - Novel Approaches in Neuro, on Tuesday, August 10, 2021 at 12:00 p.m.
  • Canaccord Genuity 41st Annual Growth Conference: fireside chat on Wednesday, August 11, 2021 at 8:00 a.m.
  • A live webcast of each event can be accessed on the investor page of Sages website at investor.sagerx.com .
  • Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.

Molecular Lab Partners LLC Reports 506% Second Quarter Growth Over Prior Quarter

Retrieved on: 
수요일, 8월 4, 2021
Natural sciences, Biotechnology, Molecular biology, Biology, Life sciences, Laboratory techniques, Amplifiers, Polymerase chain reaction, Roche

OVERLAND PARK, Kan., Aug. 4, 2021 /PRNewswire/ -- Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the second quarter of 2021.

Key Points: 
  • OVERLAND PARK, Kan., Aug. 4, 2021 /PRNewswire/ -- Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the second quarter of 2021.
  • The growth is reflective of the strong demand for In-Office PCR Testing Solutions by physicians nationwide.
  • MLP has streamlined a turn-key process that enables physicians to bring molecular PCR based testing in-house with relative ease.
  • Molecular Lab Partners LLC, a privately owned company, specializes in providing hands-on consulting services to physicians interested in bringing molecular based PCR testing in-house as an ancillary service.Their turn-key solution allows physicians to begin operating their own high complexity molecular lab in as little as three months.For additional information about Molecular Lab Partners, please visit molecularlabpartners.com.

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Retrieved on: 
수요일, 8월 4, 2021
Health sciences, Life sciences, Natural sciences, Pharmaceutical industry, Drug discovery, Clinical research, Food and Drug Administration, Clinical pharmacology, Clinical trial, Pharmacology, Drug development, ADME

Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.

Key Points: 
  • Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial.
  • These study areas include the following: Safety Pharmacology, Toxicology, CMC (Chemistry Manufacturing and Control) activities, ADME (Absorption, Distribution, Metabolism and Excretion) and Genotoxicity.
  • said Michael Redmond, CEO of Odyssey Group International
    Odyssey Group International, Inc. (OTC: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.

Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
수요일, 8월 4, 2021
Life sciences, Biotechnology, Biology, Genuity, Protein design, Biopharmaceutical, De novo

SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.

Key Points: 
  • SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.
  • An archived replay will also be available on the company website for at least 30 days following the event.
  • Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.

Oyster Point Pharma to Report Second Quarter 2021 Financial Results on August 5, 2021

Retrieved on: 
수요일, 8월 4, 2021
Life sciences, Medication, Pharmaceutical industry, Natural sciences, Health sciences, Aerie Pharmaceuticals, Two River

PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.

Key Points: 
  • PRINCETON, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021, after the market close.
  • To access the live call by phone, please dial (855) 548-1220 (US/Canada) or (602) 563-8619 (International).
  • Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.
  • Despite the large prevalence of dry eye and the burden of the disease, there remains a significant unmet need for effective therapies.